Department of Chemistry & Center for Drug Discovery & Innovation, University of South Florida, FL, USA.
Future Med Chem. 2012 Sep;4(13):1751-61. doi: 10.4155/fmc.12.124.
Alzheimer's disease (AD) is a neurodegenerative disorder and the most common form of dementia, affecting more than 5.4 million people in the USA. Although the cause of AD is not well understood, the cholinergic, amyloid and tau hypotheses were proposed to explain its development. Drug discovery for AD based on the cholinergic and amyloid theories have not been effective. In this article we summarize tau-based natural products as AD therapeutics from a variety of biological sources, including the anti-amyloid agent curcumin, isolated from turmeric, the microtubule stabilizer paclitaxel, from the Pacific Yew Taxus brevifolia, and the Streptomyces-derived Hsp90 inhibitor, geldanamycin. The overlooked approach of clearing tau aggregation will most likely be the next objective for AD drug discovery.
阿尔茨海默病(AD)是一种神经退行性疾病,也是最常见的痴呆症形式,影响了美国超过 540 万人。虽然 AD 的病因尚不清楚,但已经提出了胆碱能、淀粉样蛋白和 tau 假说来解释其发展。基于胆碱能和淀粉样蛋白理论的 AD 药物发现并没有取得成效。在本文中,我们从各种生物来源中总结了基于 tau 的天然产物作为 AD 治疗药物,包括来自姜黄的抗淀粉样蛋白药物姜黄素、来自太平洋紫杉 Taxus brevifolia 的微管稳定剂紫杉醇,以及源自链霉菌的 Hsp90 抑制剂格尔德霉素。清除 tau 聚集的这种被忽视的方法很可能成为 AD 药物发现的下一个目标。